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Nicotinamide adenine dinucleotide (NAD) is an important cofactor of energy-producing pathways. 
the redox ratio  (nAD+/NADH) reflects the cellular oxidoreductive state. Oxidative stress and redox 
dysregulation have been suggested to contribute to various neurological diseases. The assessment 
of nAD content has been recently demonstrated in large animals and human brains by 31p magnetic 
resonance spectroscopy. However, its measurement in small rodents has never been attempted. 
The purpose of this study was to investigate, in vivo, the nAD content during mouse brain 
neurodevelopment. 31P-MR-spectra were acquired in the mouse brain at postnatal days P20, P40, 
P90 and P250 at 14.1 T using a 3D-localization sequence. High spectral quality was achieved at 14.1 T. 
 nAD+ and NADH were quantified with mean Cramér-Rao lower bound of 10% and 14%, respectively. 
An increase in  nAD+/NADH was observed from P20 to P250 due to a decrease in [NADH]. The 
intracellular pH was significantly reduced with age, while the free  [Mg2+] in the brain was significantly 
increased. This study demonstrates for the first time the feasibility of the measurement of NAD 
content in vivo in mouse brains during development, which opens the prospect of longitudinally 
studying energy metabolism and redox dysfunction in mouse models of brain pathology.
Nicotinamide adenine dinucleotide (NAD) is a key component of all living cells. NADH (reduced form) and 
 NAD+ (oxidized form) are cofactors in bioenergetic pathways, and they play a fundamental role in all oxido-
reduction reactions, such as glycolysis, the tricarboxylic acid cycle and the electron transport  chain1,2. The 
redox ratio (RR;  NAD+/NADH) reflects the cellular oxidoreductive state.  NAD+ is also involved in various other 
biologically relevant processes, including calcium homeostasis, carcinogenesis, cell death, gene expression and 
immunological  functions3.
Physiological changes in redox regulation and oxidative stress, which have been highlighted in developmental 
and aging processes, are differentially regulated through childhood, adulthood or older  age4. Pathophysiological 
oxidative stress and redox dysregulation have been suggested to contribute to many neurological and psychi-
atric diseases, including schizophrenia, Parkinson’s disease and Alzheimer’s  disease5–7. An interaction between 
redox dysregulation and neuroinflammation acting through a vicious circle during brain development has also 
been described as the center of schizophrenia  pathophysiology8,9. The fact that NAD could be used as an early 
biomarker for the detection of neurological conditions that can be routinely assessed appears to be of high 
 importance10. The main source of ROS (reactive oxygen species) arises from oxidative energy metabolism in 
the mitochondria, where a large pool of NAD is used as an electron carrier. Evidence of mitochondrial dysfunc-
tion involving NAD and redox ratio anomalies was identified in neurodegenerative  conditions11,12. Moreover, 
mitochondrial function is crucial for neurogenesis and  neurodevelopment13. Redox dysregulation has a direct 
effect on cellular metabolism and ATP production.
Two ex vivo approaches have generally been used for the assessment of NAD contents: one is based on auto-
fluorescence of the intracellular NADH signal, and the other relies on biochemical analysis. Autofluorescence 
provides a weak endogenous signal in living cells that is derived mainly from mitochondrial compartments. 
This approach suffers from low detection sensitivity and limited tissue penetration, with the major drawback 
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being that  NAD+ is not  detected14. The biochemical analysis effectuated with HPLC, capillary electrophoresis or 
enzymatic cycling assays requires a tissue biopsy and some extraction prior to  analysis15–17. This process might 
lead to large quantification errors for the highly sensitive redox pairs that have been shown to be rapidly altered 
after  death18,19.
The in vivo measurement of  NAD+ peaks has been demonstrated using 1H-magnetic resonance spectroscopy 
(MRS) from the downfield region of the MR spectra (8.6 to 9.6 ppm); this method does not provide a measure-
ment of NADH, and therefore, similar to the autofluorescence approach, the RR cannot be  calculated20. The 
in vivo measurement of both NAD content and redox state has not been available until recently. Thus, there was 
major interest when 31P-MRS, a technique that allows a noninvasive measure of NAD content at high magnetic 
fields, was demonstrated in cat and human  brains21–25. The challenge of this measurement by 31P-MRS is the 
intrinsic low sensitivity of 31P, together with the fact that the  NAD+ quartet overlaps the NADH singlet, and both 
are standing as a shoulder on the right side of the α-ATP resonance signal. Therefore, the high sensitivity and 
spectral dispersion provided by the high magnetic fields and excellent shimming performance are prerequisites 
for the in vivo detection of NAD redox pairs. To date, there have been no reports in mice, mainly because the 
small brain size of a mouse challenges the feasibility of this measurement. However, it is of prime interest to apply 
this measurement to the mouse brain since they are generally used and subject to genetic modifications for the 
investigation of pathophysiology. Furthermore, in vivo measurement of these indices during brain development is 
highly valuable for the investigation of neurodevelopmental pathophysiology. Nevertheless, the measurement in 
pups is even more challenging due to the smaller size of the brain. Using the ultrahigh field to enhance sensitivity 
and spectral dispersion would facilitate the measurement of NAD, especially in small volumes.
Therefore, in this study, we first demonstrate the feasibility of the measurement of  NAD+, NADH and  NAD+/
NADH in vivo during mouse brain development at an ultrahigh magnetic field (14.1 T), where signal sensitivity 
and spectral dispersion are enhanced. Then, the evolution of the redox state and NAD content during neurode-
velopment was investigated by 31P-MRS.
We further investigated the phosphoester, intracellular pH  (pHint) and free magnesium concentrations  [Mg2+] 
that can be evaluated by 31P-MRS during mouse brain maturation. The different phosphoester metabolites (phos-
phomonoesters (PME) and phosphodiesters (PDE)) reflect membrane synthesis and degradation and can probe 
the states of membrane phospholipid metabolism and mitochondrial  function26,27. The  pHint was also determined 
because of the high dependency between redox reactions and proton concentrations.  Mg2+ is omnipresent in all 
living organisms, and regulates energy metabolism as well as mitochondrial  function28.  Mg2+ interacts with a vari-
ety of molecules, including ATP and is also a known NMDA blocker. Thus, the determination of its concentration 
will provide complementary comprehension of brain homeostasis, energy metabolism and mitochondrial  status29.
Results
Phantom validation. Figure 1 shows the comparison of experimentally measured  [NAD+], [NADH] and 
RR with their corresponding true values in the phantoms using two quantification approaches (LCModel and 
the least square fit). NAD concentrations in phantoms are given in Supplementary Table S1. The linear regres-
sion indicates good consistency between the measured and true values for both the least square fit (slope = 0.94–
1.12,  R2 = 0.98–1.00) and LCModel (slope = 0.90–0.99,  R2 = 0.97–1.00).
Assessment of quantification methods. To assess the effect of spectral signal-to-noise ratio (SNR) 
and linewidth (LW) on the quantification of NAD content, a Monte Carlo simulation was performed. Both the 
LCModel and least square fit were assessed and compared. Figure 2 shows the means and standard deviations 
of estimated levels of  NAD+, NADH, RR and total NAD under different spectral conditions. In general, the 
LCModel demonstrated a better measurement accuracy over least square fit, especially at SNR < 30, where the 
least square fit largely underestimated  NAD+ and total NAD. As expected, the measurement precision reflected 





























































Figure 1.  Comparisons between the true values of  [NAD+], [NADH] and their ratio (RR) in the phantom and 
those experimentally measured by 31P MRS with least square fitting (blue rounds and lines) and the LCModel 
(red triangles and dots). The linear slope (s) and regression coefficient  (R2) were 0.94 and 0.98 for  NAD+ with 
least square fit and 0.90 and 0.97 with LCModel; 1.12 and 1.00 for NADH with least square fit and 0.96 and 




Scientific RepoRtS |        (2020) 10:15623  | https://doi.org/10.1038/s41598-020-72492-8
www.nature.com/scientificreports/
RSD decreased (with SNR 30-100) from 6.1 to 2.4% for the LCModel quantification of  NAD+ and from 9.2 to 
2.3% for the least square fit. The RSD for NADH quantification ranged between 8.1–3.4% and 11.8–3.6%, and for 
RR quantification, a decrease from 12.1 to 4.9% and 17.4 to 4.8% was observed for LCModel and least square fit, 
respectively. Finally, the RSD of the total NAD measurement decreased from 4.0 to 1.5% for the LCModel and 
from 6.0 to 1.7% for the least square fit.
Both quantification methods perform fairly similar in terms of the measurement accuracy at various LWs. 
The quantification precision improved with narrowing of the LW and such improvement is more pronounced 
for NADH (from 10.3 to 6.2% for LCModel, from 15.0 to 11.3% for least square fit) and redox ratio (from 16.2 
to 9.8% for LCModel, from 23.2 to 19.1% for least square fit) when  LWPCr decreases from 38 to 3 Hz (Supple-
mentary Table S3).
in vivo 31P metabolite quantification during brain development. Typical in  vivo 31P spectra of 
the frontodorsal mouse brain obtained from the volume of interest (VOI) depicted in Fig.  3a are shown in 
Fig. 3b, from P20 to P250. A zoom on the NAD region of the summed spectra in the same age group is shown 
in Fig. 3c, where the differences in  NAD+ and NADH levels can be visually observed. All spectra demonstrated 
excellent sensitivity (SNR = 30–50) and spectral quality  (LWPCr = 12–18 Hz) at 14.1 T (Supplementary Table S2), 
which ensured reliable quantification of the in vivo NAD signals. The respective LCModel fits for  NAD+, NADH, 
α-ATP, baseline and fitting residual were demonstrated.
PCr concentrations determined from 1H MRS were not significantly different from P20 to P250 (P = 0.227, 
Fig. 4 and Supplementary Table S4). However, ATP levels were shown to be significantly different (P = 0.049) and 
the posttest for linear trend showed a significant decreasing trend with age (P = 0.018).
The concentrations of  NAD+, NADH,  NAD+/NADH and total NAD (Fig. 4, Supplementary Table S5) were 
quantified in the mouse brain at P20, P40, P90 and P250 with mean CRLBs of 10% for  NAD+ and 14% for NADH. 
For  NAD+, no significant difference was observed between groups. One way-ANOVA showed a significant 
difference between age groups in [NADH] (P = 0.007 together with a significant linear trend (P = 0.0008) of a 
decrease with age. The RR significantly differed (P = 0.006) between age groups and depicted a strong linear trend 
(P = 0.0006) of an increase with age. Bonferroni post hoc tests showed a significant decrease (P < 0.01) in NADH 
levels and a significant increase in the RR (P < 0.01) between P20 and P250. The total amount of NAD (tNAD) 
remained unchanged. With the inclusion of UDPG (uridine diphosphoglucose) in summed spectra analysis, 
 NAD+, NADH, RR and tNAD at each age were shown in Supplementary Table S6. From P20 to P250, NADH 
levels reduced from 0.194 to 0.043 mM, while RR increased from 2.0 to 8.9.
Phosphoesters are subject to significant changes during development. Among these measured esters (Fig. 5 
and Supplementary Fig. S1), PE (P = 0.0004) and PME (PC + PE = PME, P < 0.0001) significantly decreased with 
age, while GPC alone (P = 0.001) and its sum with GPE (GPC + GPE = PDE, P = 0.015) significantly increased 
with age. A decrease in the monoester with an increase in the diester led to a significant decrease in PME/PDE 
with age (P < 0.0001).
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Figure 2.  Quantification of  [NAD+], [NADH],  [NAD+]/[NADH] ratio (RR) and total NAD 
 ([NAD+] + [NADH]) by LCModel or the least square fit at various (a) SNR levels and (b) linewidths determined 
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The intracellular pH and the free  [Mg2+] (Fig. 6) were significantly changed with age. A reduction in the 
 pHint (P = 0.001) and an increase of the free  [Mg2+] (P = 0.003) were observed in the brain. Bonferroni post 
hoc tests showed a significant decrease in the  pHint (P < 0.01) between P20 and P90 as well as between P40 and 
P90 (P < 0.05), while a significant increase in  [Mg2+] was seen from P20 to P40 (P < 0.05) and from P20 to P250 
(P < 0.01).
-20-15-10-50510 ppm





























Figure 3.  (a) VOI location in a female mouse brain at P40 using the fsems images used for positioning. (b) 
Typical in vivo 31P MR spectra of the mouse brain from P20 to P250 at 14.1 T (black, no baseline correction, 
10 Hz line broadening). The total spectral fit (gray) determined by the LCModel, the baseline, the individual 
fits of α-ATP, NADH (red),  NAD+ (blue), and the fitting residual. (c) Zoom on the summed spectral region of 
 NAD+ and NADH with the following number of animals at a given postnatal days: P20, N = 10; P40, N = 8; P90, 
N = 8; P250, N = 5. The figure clearly depicts the changes with development in the NAD concentrations.
5
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:15623  | https://doi.org/10.1038/s41598-020-72492-8
www.nature.com/scientificreports/
Relationship between NAD content,  pHint and  [Mg2+]. At P20, an interconnectivity between  pHint, 
 [Mg2+] and NAD content was present (Fig. 7, Supplementary Fig. S2). Specifically, a strong positive correlation 
 (R2 = 0.8646; P < 0.0001) was found between  [Mg2+] and the  pHint. A positive correlation was found between 
 [Mg2+] and NADH  (R2 = 0.5323; P = 0.017). The  NAD+/NADH ratio was negatively correlated with  pHint 
 (R2 = 0.5641; P = 0.012) and  [Mg2+]  (R2 = 0.7522; P = 0.001).
pHint remained positively correlated with  [Mg2+]  (R2 = 0.6321; P = 0.010) at P40, while this correlation disap-
peared at P90 and tended to be negative at P250. At P250, the positive correlation between NADH and the  [Mg2+] 
 (R2 = 0.8276; P = 0.032) was again observed.
Discussion
This is the first in vivo study demonstrating the measurement of NAD content and redox state during mouse 
brain development. The high sensitivity and spectral resolution at 14.1 T allowed excellent spectral quality and 
permitted us to highlight the increase in the RR during development from P20 to P250 together with reductions 
in PME/PDE and  pHint and an increase in  [Mg2+].
To assess the quantification approaches for NAD content, Monte Carlo simulations were performed using 
both LCModel and least square fit. For both methods, the measurement precision reflected by the relative stand-


























































































































Figure 4.  Quantification of brain  NAD+, NADH, RR, total NAD, PCr and ATP concentrations at postnatal 
days P20, P40, P90 and P250. Stable  NAD+ and a decrease in NADH from P20 to P250 led to a strong increase 
in their ratio, while total NAD was not affected (values are the mean ± SEM); significant differences shown are 
derived from the post hoc Bonferroni correction test for multiple comparisons, **P < 0.01.
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measurements at high magnetic fields with excellent shimming performance is beneficial for NAD measurement. 
At low SNR (< 30) conditions,  NAD+ can be more accurately quantified by LCModel relative to least square fit 
(Fig. 2). The large underestimation with least square fit may mainly originate from the worse baseline estima-
tion relative to LCModel at low SNR conditions, as a simulation without inclusion of baseline (data not shown) 
provided equivalent accuracy with both methods. Note that the measurement precision of NADH was worse 
than that of  NAD+, which was because NADH has nearly half of the concentration of  NAD+, and its peak is 
closer to the intensive α-ATP resonance, posing additional challenges for its spectral fitting. Taken together, both 
quantification methods demonstrated rigorous fitting with LCModel having a superior performance at low SNR 































































Figure 5.  Quantification of brain phosphoesters showing their changes with age. Phosphomonoester (PME) 
and phosphodiester (PDE) reflect membrane synthesis and degradation, respectively. The PME/PDE ratio 
reflects decreased membrane turnover from postnatal day P20 to P250 (values are the mean ± SEM); significant 
differences shown are derived from the post hoc Bonferroni correction test for multiple comparisons *P < 0.05, 
**P < 0.01, ***P < 0.001.
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NAD+ and NADH are key components involved in many metabolic pathways. This redox couple is responsible 
for electron transfer and regulates energy metabolism. NADH generated through glycolysis, fatty acid oxidation, 
and the TCA cycle is an energy-rich molecule that contains a pair of electrons with a high transfer potential. In 
the electron transport chain, NADH is further oxidized to  NAD+ with the release of  H+ and electrons, which 
continue to drive the electron flow and then reduce  O2 to  H2O prior to ATP  synthase30. Therefore, the RR may 
serve as a probe for sensing the status of glucose  metabolism22. In this study, the RR was found to be increased 
from P20 to P250 in mouse brains, which was driven by a decrease in NADH, suggesting a development towards 
a higher oxidative brain state from childhood to  adulthood31. This observation provided the first in vivo evidence 
supporting adaptive redox regulation with age during neurodevelopment and is in agreement with in vitro results 
reported with mouse tissue and cultured  astrocytes32. The reduction of NADH implies developmental changes in 
glucose  metabolism33,34. Note that a PET study of human brain development reported that the cerebral metabolic 












































Figure 6.  Decrease in the brain intracellular pH and increase in free magnesium concentration with age (values 
are the mean ± SEM); significant differences shown are derived from the post hoc Bonferroni correction test for 
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Figure 7.  Correlation heat map at postnatal days P20, P40, P90 and P250 of  NAD+, NADH, phosphoester, 
 pHint and free magnesium  [Mg2+] content in the mouse brain. The correlation between NADH, and magnesium 
observed at P20, which disappeared at P40 and P90, reestablished at P250. The strong positive correlation 
between  pHint and magnesium observed at P20 became weaker at P40 and finally resulted in a negative 
but nonsignificant trend at P250. NADH, which was negatively correlated with PME at P20 and negatively 
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P20 corresponds to 2–3 years of human  age36. Therefore, the decline in NADH from P20 to P250 may mainly 
be attributed to the reduction of glucose utilization with maturation. Note that the NAD content and RR meas-
ured by 31P MRS contain contribution from both cytosolic and mitochondria compartments. Future study by 
performing compartment-specific manipulation in NAD or RR may facilitate interesting findings of metabolic 
consequences in different cellular  compartments37.
Using PCr levels measured from 1H-MRS, we observed a mild decrease in ATP, which was often thought to 
be stable and used as a quantification  reference22,29,38. This reduction in ATP at adulthood, which is in line with 
the reduced NADH, suggests that energy homeostasis appears to reach a lower level in the mature brain.
Furthermore, UDPG overlaps with NAD resonances especially that of NADH and has an impact on NAD 
levels. Other 31P-MRS study showed that the inclusion of UDPG in the quantification lowers the NADH level 
and leads to a higher RR  value24. Similar results were observed in the current study, with the inclusion of UDPG 
in the analysis, the NADH values reduced and RR values increased (Supplementary Table S6). The RR values are 
in good agreement with reported values in 3 and 7 months old mouse brains using  HPLC39,40. All age-dependent 
changes in NAD content and RR also remains consistent with those obtained from individual animal analysis, 
suggesting no impact of the UDPG contribution on current developmental findings.
pHint and magnesium are essential for monitoring and regulating brain physiology.[Mg2+] is closely related 
to ATP synthase, and can also bind to many proteins, including  NMDAr41,42. Thus, cell energy metabolism and 
redox state are closely linked to the availability of  Mg2+. An increase in the  pHint together with a decrease in the 
 [Mg2+] have been reported upon activation in the human visual  cortex29. To support a higher energy demand 
for sustained neuronal activity and maintain ATP homeostasis, increased ATP synthesis is required. This leads 
to more binding of  Mg2+ and  H+ with ADP and ATP, resulting in the reduction of free  [Mg2+] and  [H+]. Here, 
we reveal, in mice, very similar  pHint and  [Mg2+] values from previously described human  results29. We also 
highlighted (Fig. 6) a higher  pHint together with a lower free  [Mg2+] in young pups. This suggested that the early 
developing brain may be in a more energy demanding state than the fully adult brain, mainly for the support 
of neuronal growth and plasticity together with synaptic proliferation/pruning during brain  development43.
At P20,  pHint,  [Mg2+] and the RR were correlated (Fig. 7, Supplementary Fig. S2), suggesting that during this 
critical early developmental period, these physiological parameters are tightly regulated. The strong positive 
correlation between  pHint and  [Mg2+] observed at P20 seemed to disappear at later stages and even tended to 
be negative at P250, thus reflecting substantial changes in metabolism and the physiological environment with 
increased age.
In our study, we observed a decrease in PME with an increase in PDE (Fig. 5, Supplementary Fig. S1), which 
was consistent with the reported results in the rat brain and depicted a marked influence on membrane phos-
pholipid metabolism during brain  development44. The high PME levels observed in the young developing brain 
reflect the active synthesis of membranes and are associated with the development of all neural processes. In 
contrast, PDE levels reflecting more catabolic byproducts were rather low in the young mouse and then steadily 
rose to their adult levels. The PME/PDE ratio, which reflects membrane phospholipid turnover, was high in the 
newborn period and rapidly decreased up to P40. Thereafter, the PME/PDE ratio decreases slightly until P250, 
suggesting that membrane phospholipid breakdown proceeded slightly faster than membrane phospholipid 
synthesis in the aging process.
The results from age-merged data (Supplementary Fig. S3) showed positive correlations of PME/PDE ratio 
with NADH and  pHint.  NAD+ correlated negatively with  pHint, and a negative trend was observed between PME 
and  Mg2+. Such interconnections among all these components constituted a developmental pattern, suggesting 
that brain development requires tight and complex cellular regulation. Future studies of neurodevelopmental 
diseases could monitor this network between NAD, pH,  Mg2+ and PME/PDE, and search for interruption of this 
developmental regulatory system and implications of their role in the pathophysiology of diseases.
In conclusion, this study demonstrated for the first time the feasibility of in vivo measurement of  NAD+, 
NADH and redox state during mouse brain development by 31P-MRS at 14.1 T. This study paves the way to study 
energy metabolism and redox dysfunction in transgenic mouse models of brain pathologies and aims to develop 
translational biomarker profiles for early detection of and intervention for neurological and psychiatric diseases. 
As a noninvasive and nonradioactive strategy, the in vivo measurement of  NAD+ and NADH by 31P-MRS may 
also serve as a promising biomarker for monitoring brain energy metabolism in future neurodevelopmental 
studies with children or infants.
Methods
Phantom preparation. A set of solutions, depicted in Supplementary Table S1, with known concentra-
tions of  NAD+ (Roche Diagnostics GMBH, Mannheim, Germany, free acid grade 1, ~ 100%, lot: 11018337) and 
NADH*3H2O (Fluka biochemika, > 97%, lot: 301192 1090), were prepared by dissolving the chemicals in PBS 
(Sigma life science; D8537, Dulbecco’s phosphate buffered saline, pH 7.1–7.5) containing 9.57 mM inorganic 
phosphate (Pi), which was used as an internal reference.
Animal preparation. C57Bl6/j mice born in the local animal facility were housed in ventilated cages on a 
12-h light–dark cycle at a room temperature of 20–22 °C with 50–60% humidity. Regular chow and tap water 
were provided ad libitum.
The experiments were conducted with a cohort of males/females aged 20, 40, 90 and 250 days with body 
weights of 7–40 g. These ages correspond to different developmental stages: P20 is the end of the suckling period 
and corresponds to infant stage in human; P40 is the puberty period corresponding to the beginning of adoles-
cence; P90 corresponds to early adulthood stage in human (around 18 years old) and finally P250 corresponds to 
fully adulthood stage in human (around 30–35 years old)36,45,46. The following number of animals were scanned 
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at each age and used for statistical analysis: P20 (5 m/5 f.), P40 (4 m/5 f.), P90 (4 m/4 f.), P250 (4 m/1 f.). For 
technical reasons such as scanner availability or maintenance, some animals were not scanned at certain time 
point. As a result, this study is not purely longitudinal.
The animals were anesthetized by a mixture of air:O2 (1:1 ratio) and 0.9–1.2% isoflurane. They were then 
fixed in a mouse holder with a bite bar and two ear inserts (RAPID Biomedical GmbH, Rimpar, Germany). The 
body temperature, measured with a rectal probe, was kept at 37 ± 0.5 °C by tubing with circulating warm water. 
Spontaneous breathing was maintained at 90 ± 20 rpm by adjusting the isoflurane concentration. The respiration 
rate and body temperature were monitored by a small animal monitor (SA Instruments Inc., Stony Brook, NY, 
USA). All animal procedures were performed according to federal guidelines and were approved by the Swiss 
cantonal veterinary office.
1H and 31P MR Spectroscopy. All MR experiments were performed on a 14.1 T small animal scanner 
with a 26 cm horizontal bore (Magnex Scientific, Abingdon, United Kingdom), equipped with a 12 cm internal 
diameter gradient coil insert (400 mT/m, 120 µs) and a DirectDrive console interface (Agilent Technologies, 
Palo Alto, CA, USA). Radio frequency transmission/reception was achieved using a homebuilt geometrically 
decoupled, two single-turn loops (10 mm diameter), quadrature 1H surface coil with a linearly polarized one 
loop 31P coil (10 mm diameter).
Fast spin-echo multiple slice images were first acquired in the axial and sagittal directions for voxel positioning 
using the following parameters: repetition time of 3.3 s, echo time of 43.24 ms, echo train length of 8, interecho 
spacing of 10.81 ms, field of view of 20 × 20 mm, matrix size of 128 × 128, slice thickness of 0.4 mm, 35 slices 
and 2 averages. Local shimming in the volume of interest (VOI) was achieved using 1st- and 2nd-order shims 
with FAST(EST)MAP47.
Water suppressed 1H-MR spectra were acquired from a volume of 5.76 µL (0.9 × 4 × 1.6 mm3) centered in the 
cerebral cortex using the SPECIAL (SPin ECho full Intensity Acquired Localized spectroscopy) sequence with an 
echo time of 2.75 ms, a repetition time of 4 s and 240  averages48. VAPOR (VAriable Pulse power and Optimized 
Relaxation delays) water suppression and outer volume suppression were used prior to SPECIAL  localization49. 
The transmitter frequency was set on the water resonance to acquire unsuppressed water spectra (8 averages) 
for metabolite quantification.
31P-MR spectra were acquired using a pulse-acquire sequence (adiabatic half passage, 500 µs pulse width, 
12 kHz spectral width, 4,096 complex points) in combination with 3D-ISIS to localize the VOI in the frontodor-
sal part of the brain (Fig. 3a). The following parameters were used: voxel size of 90 µL (2.5 × 6 × 6 mm3) at P20 
and P40 and 122.5 µL (2.5 × 7 × 7 mm3) at P250, TR = 5 s, 1,600 averages (100 blocks of 16 averages, frequency 
drift and phase variation were corrected prior to the summation of spectra), transmitter offset was set on  NAD+ 
(− 8.3 ppm). For phantom experiments: TR = 15 s, 40–100 averages. For scanning NAD peaks and reference Pi 
signal, the transmitter offset was set on  NAD+ and on Pi resonances, respectively, due to the asymmetric excita-
tion profile of the adiabatic half passage pulse.
Monte Carlo simulation. To assess the accuracy and precision of spectral fitting approaches i.e. the least 
square fit and LCModel (Stephen Provencher Inc., Oakville, Ontario, Canada), Monte Carlo simulations were 
carried out. 31P free induction decay (FID) signals were simulated, including 14 metabolites, with the concentra-
tions and LW (Supplementary Table S2) calculated from the summed in vivo spectra of mouse brains as well as 
a baseline, also extracted from the summed in vivo signals. To study the effect of the SNR on the quantification 
of 31P metabolites, random Gaussian noise was added to the FID to synthesize 100 31P spectra with an SNR of 
10–100 (10/step) using a PCr LW of 13 Hz. Spectra with different LWs were simulated to study the LW effect 
on the quantification at the experimental SNR (SNR = 30). 100 spectra per point were simulated with an SNR 
of 30, starting from the LW used in the LCModel basis set (Supplementary Table S2) and increasing it in 7 steps 
of 5 Hz. The signal-to-noise ratio was defined as SNR = peak height of α-ATP (− 7.6 ppm)/standard deviation of 
noise level (− 20 to − 25 ppm).
The simulated data were then analyzed by both methods to compare the 31P spectral quantification of  NAD+ 
and NADH. For the least square fit, 31P spectra of  NAD+, NADH, α-ATP and UDPG with pseudo-Voight spectral 
shapes were simulated using published chemical shifts and J-coupling  constants21,23,24,50. These spectra were then 
used to fit baseline-corrected 31P MR spectra using a home written least square error minimization algorithm 
in MATLAB(R2017a). Briefly, the baseline, originated from short  T2* components mainly from phospholipids 
and bones, was removed by subtraction of a spline fit using the backcor() function from  MathWorks51. Then a 
region of interest ranging from − 6 to − 14 ppm (PCr was set as 0 ppm) was selected for spectral fitting using the 
lscurvefit() function from MATLAB.
For LCModel fit, a basis-set was prepared using simulated 31P spectra including PCr (phosphocreatine), 
α − ATP, β − ATP, γ − ATP,  Piint (intracellular inorganic phosphate),  Piext (extracellular inorganic phosphate), PE 
(phophothanolamine), PC (phosphocholine), GPC (glycerophosphocholine), GPE (glycerophosphoethanola-
mine), MP (membrane phospholipid), UDPG, NADH, and  NAD+, with respective linewidths (Supplementary 
Table S2)25,52.
Spectral quantification. In vivo 1H MR spectra were fitted by LCModel with a basis set containing a meas-
ured macromolecules  spectrum53 and simulated metabolites  spectra54 to determine metabolite concentrations. 
Unsuppressed water spectra were used as the quantification reference. The brain water content was measured 
at P20, P40, and P90 using the weight difference between freshly removed and fast dissected cerebral cortex 
and its residue after lyophilization (Supplementary Table S4). The water content at P250 was set as that at P90 
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assuming stable water content at adulthood. The respective water content was incorporated in the control file for 
metabolite quantification.
Apodization with a 10 Hz exponential function was applied to all 31P spectra prior to spectral quantification. 
In vivo 31P MR spectra were analyzed by LCModel using the basis-set described above. For individual animal 
analysis, UDPG was excluded due to its low SNR. To evaluate the impact of UDPG on the quantification of NAD 
content, 31P MR spectra at each age were summed and quantified with the inclusion of UDPG (Supplementary 
Table S6). The 31P metabolite levels at each age were normalized using the mean PCr level obtained from the 1H 
experiment at the respective age (Supplementary Table S4).  T1 saturation effect for metabolites with long  T1s 
(such as phosphoester) was not corrected assuming the same saturation effect for each age group. The Cramér-
Rao lower bound (CRLB) was used as an exclusion criterion, and the cutoff was set at a maximum of 30%. ATP 
level was reported as the mean of α-ATP and γ-ATP  values55.
The  pHint and free  [Mg2+] were calculated from specific chemical shift differences between metabolites. Intra-
cellular  pHint was determined by Eq. 1 from the chemical shift difference between  Piint and PCr. The parameter 
δPi was the chemical shift difference between PCr and Pi, and the constants used were pKa = 6.73, δa = 3.275, 
and δb = 5.68556.
The free  [Mg2+] concentration was calculated using the chemical shift difference between PCr and β-ATP 
(δβATP-PCr) according to Eqs. 2 and 341.
Statistical analysis. All analyses were performed in R (R version 3.6.0, 2019, https ://cran.r-proje ct.org/), 
GraphPad Prism 5 (GraphPad software, Inc.) or MATLAB (R2017a). All variables were tested by one-way 
ANOVA using age as a fixed factor. In the case of significant differences between groups, the effect of age was 
post hoc investigated between all pairs of columns using the Bonferroni correction for multiple comparisons. A 
posttest for linear trend was also effectuated followed by a linear regression along age to evaluate whether a small 
regular increase or decrease with age that would not be detected by ANOVA could be present. A linear mixed 
effect analysis was effectuated to evaluate the effect of sex, the duration of anesthesia and the time period of the 
day which did not revealed significant influence of these parameters on our cohort. The results are presented as 
the mean ± standard error of the mean unless otherwise stated. When exact p-values are not provided, significant 
differences (*) are considered for P < 0.05, very significant differences (**) for P < 0.01 and extremely significant 
differences (***) for P < 0.001.
Data availability
The data that support the plots within this paper and other findings of this study are available from the corre-
sponding author upon reasonable request.
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